Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Accurately reflects the labeled indication (MDD in adults) and several supported safety effects (somnolence; increased appetite/weight gain) and serotonin-related interactions. However, multiple claims imply symptom-cluster-based “used when” indications for poor sleep/low appetite/weight loss and suggest anxiety/insomnia prescribing patterns, which are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Mirtazapine is an antidepressant.
Supported by labeled use for treatment of major depressive disorder (MDD) in adults (1 INDICATIONS AND USAGE).
Mirtazapine is used to treat major depressive disorder (MDD) in adults.
REMERON/REMERONSolTab indicated for treatment of MDD in adults (1 INDICATIONS AND USAGE).
Mirtazapine’s primary, labeled use is depression.
Indication is MDD in adults (1 INDICATIONS AND USAGE).
Mirtazapine can increase appetite in some people.
Appetite increase reported in 17% vs 2% placebo (5.7 Increased Appetite and Weight Gain).
Mirtazapine can cause weight gain.
Weight gain of ≥7% body weight reported in 7.5% vs 0% placebo (5.7 Increased Appetite and Weight Gain).
Mirtazapine can cause drowsiness, particularly early in treatment.
Somnolence reported in 54% vs 18% placebo (5.8 Somnolence); however, the “particularly early in treatment” timing is not explicitly stated in the provided label excerpts.
Other medicines that affect serotonin may be relevant when starting mirtazapine.
Concomitant use of serotonergic drugs increases risk of serotonin syndrome (7 DRUG INTERACTIONS; Other Serotonergic Drugs and MAOIs/serotonin syndrome risk).
Unsupported Statements
Mirtazapine is used to treat major depressive disorder (MDD) in adults when depression is associated with poor sleep.
Not supported as an indication criterion in the provided label excerpts (Indications section only states MDD in adults; no symptom-cluster selection criteria shown).
Mirtazapine is used to treat major depressive disorder (MDD) in adults when depression is associated with low appetite.
Not supported as an indication criterion in the provided label excerpts.
Mirtazapine is used to treat major depressive disorder (MDD) in adults when depression is associated with significant weight loss.
Not supported as an indication criterion in the provided label excerpts.
Mirtazapine is sometimes prescribed for anxiety symptoms.
No label support for anxiety as an indication in the provided label excerpts (1 INDICATIONS AND USAGE only).
Mirtazapine has off-label uses depending on the clinician and the patient’s symptom pattern.
Off-label use is not discussed in the provided label excerpts.
Mirtazapine is sometimes prescribed for anxiety with insomnia.
No label support for anxiety as an indication in the provided label excerpts.
Mirtazapine can be chosen when sleep is a major issue.
The label excerpts discuss somnolence as a warning/precaution, not selection criteria for sleep-related indication use.
Mirtazapine may help with insomnia in some patients.
The provided label excerpts describe somnolence/impairment caution but do not claim treatment of insomnia.
Mirtazapine can be considered when appetite is low.
The label excerpts describe increased appetite/weight gain as adverse effects, not as a treatment criterion when appetite is low.
Mirtazapine side effects and other medications should be discussed with a prescriber.
No such patient counseling statement is present in the provided label excerpts.
Contradictions
Important Omissions
No contraindications, boxed warnings, or other key safety warnings (e.g., suicidal thoughts/behaviors, MAOI contraindication) are addressed in the AI claims, though the prompt here is limited to the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims suggest symptom-cluster-based prescribing decisions (sleep/appetite/weight-loss tailored use) and anxiety/insomnia prescribing, which are not supported by the provided label excerpts and could lead to inaccurate understanding of labeled indication scope. Some safety-related statements about somnolence and appetite/weight gain are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Claims that mirtazapine is used for MDD specifically when poor sleep/low appetite/significant weight loss are present, and claims about anxiety/insomnia prescribing, are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to the labeled indication (MDD in adults) and supported labeling facts (somnolence as a precaution; increased appetite/weight gain as adverse effects; serotonergic drug interaction/serotonin syndrome risk). Remove or rephrase symptom-cluster and anxiety/insomnia prescribing assertions unless supported by the full label text.